Identification of FDA-approved drugs that increase mevalonate kinase in hyper IgD syndrome

被引:1
|
作者
Politiek, Frouwkje A. [1 ,2 ]
Turkenburg, Marjolein [1 ]
Koster, Janet [1 ]
Ofman, Rob [1 ]
Waterham, Hans R. [1 ,2 ,3 ,4 ]
机构
[1] Amsterdam Univ Med Ctr, Acad Med Ctr, Dept Lab Med, Lab Genet Metab Dis, Amsterdam, Netherlands
[2] Amsterdam Gastroenterol Endocrinol & Metab, Amsterdam, Netherlands
[3] Amsterdam Reprod & Dev, Amsterdam, Netherlands
[4] Amsterdam Univ Med Ctr, Acad Med Ctr, Lab Genet Metab Dis F0 222, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
关键词
cholesterol biosynthesis; clobetasol propionate; glucocorticoids; mevalonate kinase deficiency; systemic autoinflammatory diseases; HYPERIMMUNOGLOBULINEMIA-D; CHOLESTEROL; DEFICIENCY; MUTATIONS; PHENOTYPE; SERIES; BIOSYNTHESIS; GENOTYPE; SPECTRUM; CELLS;
D O I
10.1002/jimd.12698
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mevalonate kinase deficiency (MKD) is an autoinflammatory metabolic disorder caused by bi-allelic loss-of-function variants in the MVK gene, resulting in decreased activity of the encoded mevalonate kinase (MK). Clinical presentation ranges from the severe early-lethal mevalonic aciduria to the milder hyper-IgD syndrome (MKD-HIDS), and is in the majority of patients associated with recurrent inflammatory episodes with often unclear cause. Previous studies with MKD-HIDS patient cells indicated that increased temperature, as caused by fever during an inflammatory episode, lowers the residual MK activity, which causes a temporary shortage of non-sterol isoprenoids that promotes the further development of inflammation. Because an increase of the residual MK activity is expected to make MKD-HIDS patients less sensitive to developing inflammatory episodes, we established a cell-based screen that can be used to identify compounds and/or therapeutic targets that promote this increase. Using a reporter HeLa cell line that stably expresses the most common MKD-HIDS variant, MK-V377I, C-terminally tagged with bioluminescent NanoLuc luciferase (nLuc), we screened the Prestwick Chemical Library (R), which includes 1280 FDA-approved compounds. Multiple compounds increased MK-V377I-nLuc bioluminescence, including steroids (i.e., glucocorticoids, estrogens, and progestogens), statins and antineoplastic drugs. The glucocorticoids increased MK-V377I-nLuc bioluminescence through glucocorticoid receptor signaling. Subsequent studies in MKD-HIDS patient cells showed that the potent glucocorticoid clobetasol propionate increases gene transcription of MVK and other genes regulated by the transcription factor sterol regulatory element-binding protein 2 (SREBP-2). Our results suggest that increasing the flux through the isoprenoid biosynthesis pathway by targeting the glucocorticoid receptor or SREBP-2 could be a potential therapeutic strategy in MKD-HIDS.
引用
收藏
页码:302 / 316
页数:15
相关论文
共 50 条
  • [23] An analysis of FDA-approved drugs for psychiatric disorders
    Kinch, Michael S.
    Patridge, Eric
    DRUG DISCOVERY TODAY, 2015, 20 (03) : 292 - 295
  • [25] FDA-approved drugs in 2022: A brief outline
    Al-Madhagi, Haitham Ahmed
    SAUDI PHARMACEUTICAL JOURNAL, 2023, 31 (03) : 401 - 409
  • [26] An analysis of FDA-approved drugs for cardiovascular diseases
    Kinch, Michael S.
    Surovtseva, Yulia
    Hoyer, Denton
    DRUG DISCOVERY TODAY, 2016, 21 (01) : 1 - 4
  • [27] An analysis of FDA-approved drugs for neurological disorders
    Kinch, Michael S.
    DRUG DISCOVERY TODAY, 2015, 20 (09) : 1040 - 1043
  • [28] A systematic analysis of FDA-approved anticancer drugs
    Sun, Jingchun
    Wei, Qiang
    Zhou, Yubo
    Wang, Jingqi
    Liu, Qi
    Xu, Hua
    BMC SYSTEMS BIOLOGY, 2017, 11 : 27 - 43
  • [30] Identification of FDA-Approved Drugs with Activity against Stationary Phase Bartonella henselae
    Li, Tingting
    Feng, Jie
    Xiao, Shuzhen
    Shi, Wanliang
    Sullivan, David
    Zhang, Ying
    ANTIBIOTICS-BASEL, 2019, 8 (02):